PSI CRO Enhances Mexico Hub to Support Established Local Operation

A new office was opened by PSI CRO in Mexico City at Av. Insurgentes Sur 1458, Actipán, Benito Juárez, which facilitates direct access to a local multidisciplinary team and serves as a central hub that improves coordination, speeds decision-making, and strengthens partnerships with sites and regulators across Latin America's key clinical research markets.
Mexico ranks as Latin America’s second-largest clinical trial market, supported by a commitment to annual clinical research investment from $200 million to $2 billion by 2030, which reflects growing alignment between national health priorities and global development timelines.

According to Towards Healthcare, the Latin America pharmaceutical contract manufacturing and research services market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 24.09 billion in 2026 to approximately USD 43.99 billion by 2035, representing a compound annual growth rate (CAGR) of 6.92% from 2026 to 2035. Growth is driven by the rise in chronic diseases alongside tighter financial constraints, which have driven a regional demand for affordable, cost-effective generic medications, which are heavily produced through contract manufacturers and collaboration with emerging biotech of small and mid-sized companies for partnering with Contract Development and Manufacturing Organizations (CDMOs) to accelerate the discovery and commercialization of new molecules.

About PSI

PSI CRO is the leading global contract research organization and is a major player in the Latin American pharmaceutical and clinical research market. Specializing in complex Phase II and Phase III clinical trials, PSI focuses on oncology, immunology, and rare diseases. The organisation is committed to being the best CRO in the world, as measured by its employees, customers, investigators, and vendors.

The company specializes in pivotal phase 2 and phase 3 clinical trials in oncology, hematology, gastroenterology, immunology, infectious diseases, neuroscience, and other indications. PSI provides expertise in complex trials at the forefront of precision medicine, including platform and umbrella designs, trials in targeted immunotherapy, radiopharmaceuticals, and cell and gene therapies. The expansion is a testament to PSI CRO's commitment to delivering quality and reliable clinical trial services worldwide.

A recent report by Towards Healthcare highlights that the Latin America pharmaceutical contract manufacturing and research services market is witnessing growth due to the growing geriatric population and an increase in the prevalence of chronic diseases are driving demand for affordable generic drugs and biosimilars, necessitating outsourced manufacturing with cost effiency labor, and operational costs compared to North America and Europe, combined with geographical proximity, make the region highly attractive for nearshoring initiatives.